Nanoscale Encasement and Targeted Delivery of Multifunctional Therapeutic Agents

这个研究小组将开发新型多功能治疗和诊断剂， 纳米级传输装置。每个项目的中心目标是设计和评估各种“智能” 纳米级货物仓（纳米仓）可以靶向癌细胞，与它们结合，随后卸载高达 超过500000分子的细胞毒性或放射性药剂。合成纳米纤维素组 将制造新的单克隆抗体生物结合物，并与临床医生合作测试其功效 他们现在在细胞培养试验和临床上使用抗体。该方法将结合联合收割机新的装载 已建立的抗癌药物的策略（O 'Halloran）与理论方法（Schatz）设计新的 脂质体，用于合成关节脂质体的先进脂质前体技术（MacDonald）， 开发聚合物胶束技术（Nguyen），用于聚合物圆柱体的纳米纤维方法 （奥多姆）。这些药物中的每一种最初将与临床小组合作进行评估（Singhal， Tallman，罗森）在白血病和多发性骨髓瘤的细胞培养模型中。具体的代理商也将 在实体瘤模型中评估。拟议中的“纳米彬”货物系统也可以容纳生物制剂， 影响肿瘤和/或其直接微环境的肽、酶和生长抑制因子。 因此，这些新材料具有为必须治疗的癌症提供持续治疗的潜力 慢性的

This team of investigators will develop novel multifunctional therapeutic and diagnostic agents encased in nanoscale delivery devices. The central goal of each project is to engineer and evaluate a variety of "smart" nanoscale cargo bins (nanobins) that can target cancer cells, bind to them and subsequently unload up to more 500000 molecules of a cytotoxic or radiopharmaceutical agents. The synthetic nanofabrication group will make new bioconjugates of monoclonal antibodies and test their efficacy in collaboration with clinicians who use antibodies now in cell culture assay and in the clinic. The approach will combine new loading strategies for established anticancer drugs (O'Halloran) with theoretical approaches (Schatz) to design novel liposomes, advanced lipid precursors technology for the synthesis of articulated liposomes (MacDonald), development of polymer micelle technology (Nguyen), nanofabrication methods for polymer cylinders (Odom). Each of these agents will initially be evaluated in collaboration with the clinical groups (Singhal, Tallman, Rosen) in cell culture models for leukemia and multiple myeloma. Specific agents will also be evaluated in solid tumor models. The proposed 'Nanobin' cargo systems can also house biological agents, peptides, enzymes and growth-inhibiting factors that impact a tumor and/or its immediate microenvironment. These new materials thus have the potential of providing sustained therapy for cancers that must be treated chronically.